These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 18094216)

  • 21. Sample size calculations for crossover thorough QT studies: satisfaction of regulatory threshold and assay sensitivity.
    Anand SP; Murray SC; Koch GG
    J Biopharm Stat; 2010 May; 20(3):587-603. PubMed ID: 20358438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61133-4. PubMed ID: 16237859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecularly targeted oncology therapeutics and prolongation of the QT interval.
    Strevel EL; Ing DJ; Siu LL
    J Clin Oncol; 2007 Aug; 25(22):3362-71. PubMed ID: 17664484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Severe effects of terfenadine overdose on the heart].
    Feychting K; Myrenfors P
    Lakartidningen; 1992 Nov; 89(45):3848. PubMed ID: 1460997
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of six commonly used QT correction models and their parameter estimation methods.
    Wang D; Taubel J; Arezina R
    J Biopharm Stat; 2012; 22(6):1148-61. PubMed ID: 23075014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. QT as a safety biomarker in drug development.
    Whellan DJ; Green CL; Piccini JP; Krucoff MW
    Clin Pharmacol Ther; 2009 Jul; 86(1):101-4. PubMed ID: 19474784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies.
    Shah RR; Morganroth J
    Br J Clin Pharmacol; 2013 Apr; 75(4):959-65. PubMed ID: 22905923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Electrocardiographic assessment for therapeutic proteins--scientific discussion.
    Rodriguez I; Erdman A; Padhi D; Garnett CE; Zhao H; Targum SL; Balakrishnan S; Strnadova C; Viner N; Geiger MJ; Newton-Cheh C; Litwin J; Pugsley MK; Sager PT; Krucoff MW; Finkle JK
    Am Heart J; 2010 Oct; 160(4):627-34. PubMed ID: 20934555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Olshansky B; Serra DB
    Clin Pharmacol Ther; 2008 Feb; 83(2):231-2; author reply 233. PubMed ID: 18043690
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development.
    Curigliano G; Spitaleri G; Fingert HJ; de Braud F; Sessa C; Loh E; Cipolla C; De Pas T; Goldhirsch A; Shah R
    Eur J Cancer; 2008 Mar; 44(4):494-500. PubMed ID: 18024014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study.
    Hinterseer M; Thomsen MB; Beckmann BM; Pfeufer A; Schimpf R; Wichmann HE; Steinbeck G; Vos MA; Kaab S
    Eur Heart J; 2008 Jan; 29(2):185-90. PubMed ID: 18156612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sample size and power estimation in "thorough" QT/QTc studies with parallel group design.
    Hosmane B; Locke C; Chiu YL
    J Biopharm Stat; 2010 May; 20(3):578-86. PubMed ID: 20358437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of positive controls in assessing assay sensitivity in ICH S7B and ICH E14 guidance for evaluation of QT/QTc interval prolongation.
    Chiang AY; Mallinckrodt CH; Dmitrienko AA; Leishman DJ
    J Pharmacol Toxicol Methods; 2010; 62(2):143-7. PubMed ID: 20570744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The importance of routine QT interval measurement in rhythm interpretation.
    Hutton DM
    Dynamics; 2008; 19(3):29-33. PubMed ID: 18773713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Psychotropic drugs and the risk of arrhythmias].
    Toivonen L
    Duodecim; 2002; 118(12):1223-4. PubMed ID: 12239813
    [No Abstract]   [Full Text] [Related]  

  • 36. Identifying patients at risk for QT interval prolongation: case studies.
    Flyer JL
    J Fam Pract; 2005 Jun; Suppl():S18-9. PubMed ID: 15938991
    [No Abstract]   [Full Text] [Related]  

  • 37. Near-thorough QT study as part of a first-in-man study.
    Malik M; Hnatkova K; Ford J; Madge D
    J Clin Pharmacol; 2008 Oct; 48(10):1146-57. PubMed ID: 18757785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical value of QT dispersion: new perspectives on the assessment of cardiac repolarization more than 75 years after Bazett's formula.
    Jordaens LJ
    Europace; 1999 Apr; 1(2):73-6. PubMed ID: 11228860
    [No Abstract]   [Full Text] [Related]  

  • 39. Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research Consortium.
    Heller S; Darpö B; Mitchell MI; Linnebjerg H; Leishman DJ; Mehrotra N; Zhu H; Koerner J; Fiszman ML; Balakrishnan S; Xiao S; Todaro TG; Hensley I; Guth BD; Michelson EL; Sager P
    Am Heart J; 2015 Jul; 170(1):23-35. PubMed ID: 26093861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety Pharmacology World Europe 2008--Healthcare Communications' Second Annual Conference.
    Lakeram M
    IDrugs; 2009 Jan; 12(1):26-8. PubMed ID: 19127501
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.